Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab quality-of-life study in migraine with comorbid fibromyalgia, chronic fatigue, or irritable bowel syndrome
2019-001820-36Phase 4Terminated
- Sponsor
- Novartis
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of erenumab in migraine and chronic migraine, sponsored by Novartis. Primary endpoint: Clinically meaningful improvement in MSQ 2.1 domains at 6 and 12 months. Started Jul 2019; status: terminated.
02
Drugs
erenumab
03
Conditions
migrainechronic migraine
Beyond the preview
Go deeper on 2019-001820-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001820-36.